SCHEMBL587731

SCHEMBL587731

CC[C@@H](O)[C@](C)(N)C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.46
MEN1 O00255 2/20 0.34
ALDH1A1 P00352 2/20 0.34
CYP1A2 P05177 2/20 0.34
KMT2A Q03164 2/20 0.34
GGT1 P19440 1/20 0.34
THRB P10828 1/20 0.34
ACACB O00763 1/20 0.32
ACACA Q13085 1/20 0.32
CA2 P00918 2/20 0.32
MAPK1 P28482 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C19 P33261 1/20 0.32
HIF1A Q16665 1/20 0.32
ARG1 P05089 1/20 0.31
ARG2 P78540 1/20 0.31
CA1 P00915 1/20 0.31
SLC1A3 P43003 1/20 0.31
SLC1A2 P43004 1/20 0.31
SLC1A1 P43005 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5051493 1.00 TSHR (0.46) TSHRMEN1ALDH1A1CYP1A2KMT2A
SCHEMBL1604360 0.82 CHRM1 (0.39) TSHRMEN1ALDH1A1CYP1A2KMT2A
SCHEMBL7532147 0.78 TSHR (0.42) TSHRMEN1ALDH1A1CYP1A2KMT2A
SCHEMBL5167196 0.78 TSHR (0.42) TSHRMEN1ALDH1A1CYP1A2KMT2A
SCHEMBL27665293 0.78 ALDH1A1 (0.35) TSHRMEN1ALDH1A1CYP1A2KMT2A
SCHEMBL202556 0.76 ALDH1A1 (0.34) TSHRMEN1ALDH1A1CYP1A2KMT2A
Hydrochloric Acid SCHEMBL28842189 0.76 ALDH1A1 (0.34) TSHRMEN1ALDH1A1CYP1A2KMT2A
SCHEMBL22636108 0.76 ALDH1A1 (0.34) TSHRMEN1ALDH1A1CYP1A2KMT2A
SCHEMBL20854287 0.76 ALDH1A1 (0.34) TSHRMEN1ALDH1A1CYP1A2KMT2A
Hydrochloric Acid SCHEMBL29880532 0.76 ALDH1A1 (0.34) TSHRMEN1ALDH1A1CYP1A2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748375-B2 Methods for affecting body composition using amylin agonists AMYLIN PHARMACEUTICALS, LLC (US) 2014-06-10 US disclosed
EP-1814590-B2 TREATMENT OF OBESITY AND RELATED DISORDERS AMYLIN PHARMACEUTICALS INC (US) 2013-12-11 EP disclosed
US-8598120-B2 Methods for treatment using amylin family peptides AMYLIN PHARMACEUTICALS, LLC (US) 2013-12-03 US disclosed
US-8394765-B2 Methods of treating obesity with two different anti-obesity agents AMYLIN PHARMACEUTICALS LLC (US) 2013-03-12 US disclosed
US-20120196796-A1 AMYLIN FAMILY PEPTIDES AND METHODS FOR MAKING AND USING THEM AMYLIN PHARMACEUTICALS, INC. (US) 2012-08-02 US disclosed
US-20120071401-A1 AMYLIN AGONIST COMPOUNDS FOR ESTROGEN-DEFICIENT MAMMALS Amylin Pharamaceuticals, Inc. (US) 2012-03-22 US disclosed
US-20120053118-A1 METHODS FOR AFFECTING BODY COMPOSITION USING AMYLIN AGONISTS AMYLIN PHARMACEUTICALS, INC. (US) 2012-03-01 US disclosed
EP-2416797-A2 AMYLIN AGONIST COMPOUNDS FOR ESTROGEN-DEFICIENT MAMMALS Amylin Pharmaceuticals, Inc. (US) 2012-02-15 EP disclosed
US-8114958-B2 Therapy for metabolism disorders; obesity; diabetes; cardovascular disordrs; eating disorders; hypoglycemic agents; hypotensive agents; dyslipidemia; sleep disorders; respiraotry system disorders; osteoarthritis; insulin resistance AMYLIN PHARMACEUTICALS, INC. (US) 2012-02-14 US disclosed
EP-2286838-A2 Treatment of obesity and related disorders AMYLIN PHARMACEUTICALS, INC. (US) 2011-02-23 EP disclosed
EP-1814590-B1 TREATMENT OF OBESITY AND RELATED DISORDERS AMYLIN PHARMACEUTICALS INC (US) 2009-04-08 EP disclosed
US-20080274952-A1 Amylin Family Peptides And Methods For Making And Using Them AMYLIN PHARMACEUTICALS, INC. (US) 2008-11-06 US disclosed
US-20080207512-A1 Methods for Treating Obesity and Obesity Related and Disorders AMYLIN PHARMACEUTICALS, INC. (US) 2008-08-28 US disclosed
EP-1954313-A1 TREATMENT OF OBESITY AND RELATED DISORDERS Amylin Pharmaceuticals, Inc. (US) 2008-08-13 EP disclosed
EP-1814590-A2 TREATMENT OF OBESITY AND RELATED DISORDERS Amylin Pharmaceuticals, Inc. (US) 2007-08-08 EP disclosed
WO-2007055743-A2 TREATMENT OF OBESITY AND RELATED DISORDERS AMYLIN PHARMACEUTICALS, INC. (US) 2007-05-18 WO disclosed
WO-2007055728-A1 TREATMENT OF OBESITY AND RELATED DISORDERS AMYLIN PHARMACEUTICALS, INC. (US) 2007-05-18 WO disclosed
EP-1716172-A1 AMYLIN FAMILY PEPTIDES AND METHODS FOR MAKING AND USING THEM Amylin Pharmaceuticals, Inc. (US) 2006-11-02 EP disclosed
WO-2006083254-A1 AMYLIN FAMILY PEPTIDES AND METHODS FOR MAKING AND USING THEM AMYLIN PHARMACEUTICALS, INC. (US) 2006-08-10 WO disclosed
WO-2006052608-A2 TREATMENT OF OBESITY AND RELATED DISORDERS AMYLIN PHARMACEUTICALS, INC. (US) 2006-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071401-A1 AMYLIN AGONIST COMPOUNDS FOR ESTROGEN-DEFICIENT MAMMALS BDNF, ESR1, CYP19A1 TSHR 1402/4885MEN1 505/4885ALDH1A1 3219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.